(Q39117246)

9 September 2017

MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells (English)

1 reference

9 September 2017

1 reference

1 reference

Yu-mei Rao

1

1 reference

9 September 2017

Hui-rong Shi

series ordinal

2

1 reference

9 September 2017

Mei Ji

series ordinal

3

1 reference

9 September 2017

Cai-hong Chen

series ordinal

4

1 reference

9 September 2017

1 August 2013

1 reference

Journal of Huazhong University of Science and Technology. Medical Sciences

9 September 2017

1 reference

9 September 2017

33

1 reference

9 September 2017

4

1 reference

9 September 2017

567-572

1 reference

https://scigraph.springernature.com/pub.10.1007/s11596-013-1160-5

9 September 2017

0 references

cites work

Biological characterization of ovarian cancer: prognostic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

microRNAs as novel epigenetic biomarkers for human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

Growth-promoting role of the miR-106a~363 cluster in Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

Determination of reference microRNAs for relative quantification in porcine tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

miR-106a overexpression and pRB downregulation in sporadic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

miR-106a is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

MiR-106a is an independent prognostic marker in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1160-5

Inhibitory effects of microRNA-34a on cell migration and invasion of invasive urothelial bladder carcinoma by targeting Notch1

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23904379

12 December 2020

inferred from PubMed ID database lookup

Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23904379

12 December 2020

inferred from PubMed ID database lookup

Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23904379

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S11596-013-1160-5

1 reference

release_67zwkdq7mja3tepl4wh47ly42a

9 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/67zwkdq7mja3tepl4wh47ly42a

24 November 2022

mapped directly with Wikidata item

1 reference